Pathogen resistance – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:16:31 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Pathogen resistance – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Oral Fecal Microbiota Transplantation in Patients Colonized with Multi-Drug Resistant Bacteria https://clinicaltrials.eu/trial/study-on-fecal-transplantation-using-allogeneic-fecal-microbiota-to-remove-superbugs-in-patients-with-multidrug-resistant-gram-negative-bacteria-colonization/ Wed, 29 Apr 2026 15:05:20 +0000 https://clinicaltrials.eu/trial/study-on-fecal-transplantation-using-allogeneic-fecal-microbiota-to-remove-superbugs-in-patients-with-multidrug-resistant-gram-negative-bacteria-colonization/ This study focuses on patients who have multidrug-resistant gram-negative bacteria (MDR-GNB) in their digestive system. These bacteria include extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) and carbapenem-resistant Enterobacteriaceae (CRE), which are difficult to treat with common antibiotics.

The study investigates whether fecal microbiota transplant (FMT) can remove these resistant bacteria from the body. FMT is a treatment that uses healthy gut bacteria from donors to restore balance in the patient’s digestive system. The treatment is given in the form of oral capsules that contain processed stool material from healthy donors.

During the study, participants will receive either the fecal microbiota capsules or placebo capsules. The treatment involves taking multiple capsules by mouth over two days. The main goal is to determine if this treatment can eliminate the resistant bacteria from the body when checked approximately one month after treatment.

]]> Study on Piperacillin-Tazobactam and Temocillin for Treating Severe Infections in ICU Patients with ESBL-Producing Gram-Negative Bacteria https://clinicaltrials.eu/trial/study-on-piperacillin-tazobactam-and-temocillin-for-treating-severe-infections-in-icu-patients-with-esbl-producing-gram-negative-bacteria/ Wed, 29 Apr 2026 14:58:57 +0000 https://clinicaltrials.eu/trial/study-on-piperacillin-tazobactam-and-temocillin-for-treating-severe-infections-in-icu-patients-with-esbl-producing-gram-negative-bacteria/ This clinical trial is focused on treating severe infections caused by a specific type of bacteria known as extended-spectrum beta-lactamase-producing Gram-negative Enterobacteriaceae. These infections are often found in patients who are in the intensive care unit (ICU). The study is exploring the use of two alternative treatments to a commonly used antibiotic called carbapenem. The treatments being tested are piperacillin/tazobactam and temocillin. The goal is to see if these alternatives are just as effective as carbapenem in treating these severe infections.

Participants in the study will receive one of the treatments, which are administered through an infusion, a method where the medication is delivered directly into the bloodstream. The study will last for a maximum of 21 days, during which the health and recovery of the participants will be closely monitored. The main focus is to compare the effectiveness of the treatments in terms of survival rates and to ensure that the alternative treatments do not lead to higher mortality compared to the standard carbapenem treatment.

Throughout the study, researchers will also observe other factors such as the length of stay in the ICU and hospital, any side effects from the medications, and the overall recovery process. The study aims to provide valuable information on whether these alternative treatments can be safely used in place of carbapenem for patients with these severe infections.

]]>